DC Devices Inc., a Tewksbury, Mass.-based medical device company developing structural heart devices, secured $9m in financing.
Backers included Lumira Capital and existing investors Third Rock Ventures and General Catalyst. In conjunction with the funding, Gerry Brunk, managing director of Lumira Capital, has joined the DC Devices board of directors.
The company intends to use the capital to accelerate development and ongoing clinical evaluation of its first trans-catheter device for the treatment of diastolic heart failure (DHF), also known as heart failure with preserved ejection fraction (HFpEF).
Led by George Fazio, president and CEO, DC Devices develops a proprietary, minimally invasive InterAtrial Shunt Device (IASD™) system to treat DHF/HFpEF. The IASD system works to relieve increased left atrial pressure, the main cause of DHF/HFpEF symptoms, by placing a permanent implant in the atrial septum designed to reduce the elevated pressure and relieve symptoms. The system allows physicians to perform this trans-catheter treatment without open-heart surgery and in a controlled fashion using standard interventional cardiology techniques.
Brunk joined David Celermajer, M.D., co-founder, DC Devices; Fazio; Paul LaViolette, partner, SV Life Sciences, who serves as chairman; Mark Levin, partner, Third Rock Ventures; and Hemant Taneja, managing director, General Catalyst.